NDA vs BLA Applications

Regulatory

Understanding the difference between NDA (New Drug Application) and BLA (Biologics License Application) is essential for tracking FDA drug approvals and understanding biotech pipelines.

Overview

The FDA uses different application types based on the nature of the therapeutic product:

Feature	NDA	BLA
Full Name	New Drug Application	Biologics License Application
Product Type	Small molecule drugs	Biologics (proteins, antibodies)
Regulated By	CDER	CBER (or CDER for therapeutic biologics)
Exclusivity	5 years (NCE)	12 years
Generic/Biosimilar	ANDA (generics)	aBLA (biosimilars)

New Drug Application (NDA)

What Qualifies as an NDA?

NDAs are submitted for small molecule drugs - chemically synthesized compounds with defined molecular structures.

Examples

Aspirin - Acetylsalicylic acid
Lipitor (atorvastatin) - Cholesterol medication
Viagra (sildenafil) - Erectile dysfunction
Prozac (fluoxetine) - Antidepressant

NDA Components

Section	Content
Chemistry (CMC)	Manufacturing, stability, quality control
Nonclinical	Animal studies, pharmacology, toxicology
Clinical	Phase 1, 2, 3 trial data
Labeling	Proposed prescribing information
Safety Update	Latest safety data

Key Point: Small molecules can be exactly replicated, which is why generic drugs are possible and have a simpler approval pathway (ANDA).

Biologics License Application (BLA)

What Qualifies as a BLA?

BLAs are submitted for biologics - products derived from living cells or organisms.

Types of Biologics

Monoclonal antibodies (e.g., Humira, Keytruda)
Vaccines (e.g., COVID-19 vaccines)
Gene therapies (e.g., Luxturna, Zolgensma)
Cell therapies (e.g., CAR-T treatments)
Recombinant proteins (e.g., insulin, EPO)

BLA Components

Section	Content
Product Description	Characterization of biologic
Manufacturing	Cell lines, fermentation, purification
Clinical Data	Efficacy and safety trials
Immunogenicity	Antibody formation data
Labeling	Proposed prescribing information

Key Point: Biologics are complex and cannot be exactly replicated. Biosimilars must demonstrate "no clinically meaningful differences" rather than exact equivalence.

Key Differences

Manufacturing Complexity

Aspect	NDA (Small Molecule)	BLA (Biologic)
Production	Chemical synthesis	Living cells
Size	~500 daltons	25,000-150,000 daltons
Complexity	Simple structure	Complex 3D structure
Reproducibility	Exact copies possible	Minor variations normal
Storage	Often room temperature	Usually refrigerated

Regulatory Pathway

Aspect	NDA	BLA
Review Division	CDER	CBER or CDER
Exclusivity Period	5 years (NCE)	12 years
Generic/Biosimilar Path	ANDA (505(j))	aBLA (351(k))
Interchangeability	Automatic substitution	Requires additional studies

Special Application Types

505(b)(2) NDA

A hybrid application that can rely on:

Published literature
FDA's prior findings for another drug
New clinical studies

Used for:

New formulations
New routes of administration
New combinations

Supplemental Applications

Type	Purpose
sNDA	New indication, formulation for approved NDA
sBLA	New indication, formulation for approved BLA

Exclusivity and Patent Protection

NDA Exclusivity

Type	Duration	Trigger
NCE (New Chemical Entity)	5 years	First approval of active ingredient
New Clinical Studies	3 years	New clinical investigations
Orphan Drug	7 years	Orphan designation
Pediatric	+6 months	Pediatric studies conducted

BLA Exclusivity

Type	Duration	Trigger
Reference Product	12 years	First approval of biologic
First Interchangeable	1 year	First interchangeable biosimilar
Orphan Drug	7 years	Orphan designation
Pediatric	+6 months	Pediatric studies conducted

Important: The 12-year biologic exclusivity is a major competitive advantage. Generic competition (biosimilars) faces higher barriers than traditional generics.

Investment Implications

Why It Matters

Factor	NDA Products	BLA Products
Development Cost	Lower (~$1-2B)	Higher (~$2-3B)
Manufacturing	Easier to scale	Complex facilities
Generic/Biosimilar Risk	Higher (5 years)	Lower (12 years)
Pricing Power	Erodes faster	More durable
Revenue Potential	Variable	Often blockbuster

Trends in Drug Development

The industry has shifted toward biologics:

2000: ~20% of new approvals were biologics
2023: ~40% of new approvals are biologics
Oncology and immunology heavily biologic-focused

Summary

Understanding NDA vs BLA helps investors:

NDAs = Small molecules, 5-year exclusivity, simpler manufacturing
BLAs = Biologics, 12-year exclusivity, complex production
505(b)(2) = Hybrid pathway for modified drugs
Biosimilars face higher barriers than generics
Industry trend toward more biologics

← Previous: Advisory Committees

Next: Clinical Trial Phases →